BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BeOne Medicines readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies BeOne Medicines's drugs run\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04973605-2909@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Beqalzi (Sonrotoclax): Phase 1/2 readout est. (NCT04973605)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1/2.\nStudy: A Phase 1b/2 Study o
 f Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With 
 Dexamethasone Plus Carfilzomib\, Dexamethasone Plus Daratumumab\, and Dexa
 methasone Plus Pomalidomide in Multiple Myeloma\nEstimated primary complet
 ion: November 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 onrotoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT04973605
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06637501-2909@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT06637501)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Chronic Lymphocytic Leukemia.
 \nStudy: A Study to Investigate Sonrotoclax Combined With Zanubrutinib Ver
 sus Zanubrutinib Alone in Participants With Previously Untreated Chronic L
 ymphocytic Leukemia\nEstimated primary completion: November 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06637501
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06695845-2201@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT06695845)
DESCRIPTION:Zanidatamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06695845
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04170283-2010@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT04170283)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: A Study to Evaluate Long-term S
 afety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Wh
 o Participated in BeiGene Parent Studies of Zanubrutinib\nEstimated primar
 y completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04170283
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06427941-2010@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT06427941)
DESCRIPTION:Tislelizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 A Phase 1/2 Study of BGB-B2033\, Alone or in Combination With Tislelizumab
  With or Without Bevacizumab\, in Participants With Advanced or Metastatic
  Solid Tumors\nEstimated primary completion: 31 March 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06427941
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05379985-2216@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT05379985)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study of RMC-6236 in Patients With Advanced Solid Tumors Harbor
 ing Specific Mutations in RAS\nEstimated primary completion: 31 May 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05379985
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06162221-2216@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT06162221)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutat
 ed NSCLC\nEstimated primary completion: June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/daraxonrasib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06162221
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05707377-10908@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Brukinsa (zanubrutinib): Phase 2/3 readout est. (NCT05707377)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2/3.\nStudy: A Study to Examine
  the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Memb
 ranous Nephropathy\nEstimated primary completion: October 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05707377
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07043400-2010@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07043400)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: A Study to Investigate Tisleliz
 umab Administered as Subcutaneous Injection Versus Intravenous Infusion Pl
 us Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gas
 troesophageal Junction Adenocarcinoma\nEstimated primary completion: 30 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07043400
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06881784-2216@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Rasonque (Daraxonrasib): Phase 3 readout est. (NCT06881784)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSC
 LC (RASolve 301)\nEstimated primary completion: 1 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06881784
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102381-2201@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20271229
DTEND;VALUE=DATE:20271230
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT07102381)
DESCRIPTION:Zanidatamab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: A 
 Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy 
 in Participants With HER2-positive Breast Cancer\nEstimated primary comple
 tion: 29 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/zanidatamab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07102381
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07733180-2010@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07733180)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: A Study Investigating Alternate Schedules of Tislelizumab Plus Chemo
 therapy in Japanese Patients With First-line Advanced ESCC\nEstimated prim
 ary completion: 28 February 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07733180
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07911683-2390@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:BGB-B2033: Phase 2 readout est. (NCT07911683)
DESCRIPTION:BGB-B2033\, phase 2\, Hepatocellular Carcinoma.\nStudy: Study E
 valuating the Efficacy and Safety of BGB-B2033 in Participants With Advanc
 ed Hepatocellular Carcinoma\nEstimated primary completion: 31 March 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/bgb-b2033#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07911683
URL:https://assetmemo.bio/drug/bgb-b2033#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07491445-2216@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Rasonque (Daraxonrasib): Phase 3 readout est. (NCT07491445)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 3\, Pancreatic Ductal Adenocarc
 inoma.\nStudy: Study of Daraxonrasib and Daraxonrasib + GnP as First-line 
 Treatment in Patients With Metastatic Pancreatic Adenocarcinoma\nEstimated
  primary completion: April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/daraxonrasib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07491445
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06435429-2201@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Zanidatamab: Phase 3 readout est. (NCT06435429)
DESCRIPTION:Zanidatamab\, phase 3\, HER2-Positive Breast Cancer.\nStudy: A 
 Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab\, Ea
 ch in Combination With Physician's Choice Chemotherapy\, for the Treatment
  of Participants With Metastatic HER2-positive Breast Cancer\nEstimated pr
 imary completion: 28 April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06435429
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05100862-10908@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Brukinsa (zanubrutinib): Phase 3 readout est. (NCT05100862)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 3\, Follicular Lymphoma.\nStudy
 : A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituxima
 b in Participants With Relapsed/Refractory Follicular or Marginal Zone Lym
 phoma\nEstimated primary completion: July 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05100862
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04771130-2909@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Beqalzi (Sonrotoclax): Phase 1/2 readout est. (NCT04771130)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1/2\, Acute Myeloid Leukemia.\nSt
 udy: A Study of BGB-11417 in Participants With Myeloid Malignancies\nEstim
 ated primary completion: 31 August 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04771130
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742996-2909@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Beqalzi (Sonrotoclax): Phase 3 readout est. (NCT06742996)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 3\, Mantle Cell Lymphoma.\nStudy:
  A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubr
 utinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Ref
 ractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)\nEstimated primary completi
 on: 31 August 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 onrotoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06742996
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445062-2216@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT06445062)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Pancreatic Ductal Adenoca
 rcinoma.\nStudy: Study of RAS(ON) Inhibitors in Patients With Gastrointest
 inal Solid Tumors\nEstimated primary completion: 30 September 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06445062
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06128551-2216@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT06128551)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study of Elironrasib and Daraxonrasib as Monotherapies and Comb
 ination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumor
 s\nEstimated primary completion: December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/daraxonrasib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06128551
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06282575-2201@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Zanidatamab: Phase 3 readout est. (NCT06282575)
DESCRIPTION:Zanidatamab\, phase 3\, Biliary Tract Cancer.\nStudy: Efficacy 
 and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-o
 f-care Therapy for Advanced HER2-positive Biliary Tract Cancer\nEstimated 
 primary completion: 1 December 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06282575
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06634589-2909@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20281202
DTEND;VALUE=DATE:20281203
SUMMARY:Beqalzi (Sonrotoclax): Phase 1/2 readout est. (NCT06634589)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1/2.\nStudy: A Study to Investiga
 te Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination Wit
 h Other Agents in Participants With Relapsed or Refractory B-Cell Malignan
 cies\nEstimated primary completion: 2 December 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06634589
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07805954-2216@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Rasonque (Daraxonrasib): Phase 3 readout est. (NCT07805954)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 3\, Pancreatic Ductal Adenocarc
 inoma.\nStudy: Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236
 ) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metasta
 tic KRAS G12D-Mutated Pancreatic Adenocarcinoma\nEstimated primary complet
 ion: March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dara
 xonrasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07805954
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492641-2389@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:BGB-43395: Phase 3 readout est. (NCT07492641)
DESCRIPTION:BGB-43395\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients Wit
 h Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Pri
 or Treatment for Advanced or Metastatic Disease\nEstimated primary complet
 ion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bgb-
 43395#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07492641
URL:https://assetmemo.bio/drug/bgb-43395#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07397338-2216@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT07397338)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study of RAS(ON) Inhibitors in Combination With Ivonescimab in 
 Patients With Solid Tumors\nEstimated primary completion: May 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07397338
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07252232-2216@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20290510
DTEND;VALUE=DATE:20290511
SUMMARY:Rasonque (Daraxonrasib): Phase 3 readout est. (NCT07252232)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 3\, Pancreatic Ductal Adenocarc
 inoma.\nStudy: Study of Daraxonrasib (RMC-6236) in Patients With Resected 
 Pancreatic Ductal Adenocarcinoma (PDAC)\nEstimated primary completion: 10 
 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daraxonrasi
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 252232
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836530-2390@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20290921
DTEND;VALUE=DATE:20290922
SUMMARY:BGB-B2033: Phase 3 readout est. (NCT07836530)
DESCRIPTION:BGB-B2033\, phase 3\, Hepatocellular Carcinoma.\nStudy: Study C
 omparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular
  Carcinoma\nEstimated primary completion: 21 September 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/bgb-b2033#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07836530
URL:https://assetmemo.bio/drug/bgb-b2033#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943872-2909@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Beqalzi (Sonrotoclax): Phase 3 readout est. (NCT06943872)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 3\, Chronic Lymphocytic Leukemia.
 \nStudy: A Study to Investigate Progression-Free Survival With Sonrotoclax
  Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax 
 Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chron
 ic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)\nEsti
 mated primary completion: 30 September 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06943872
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06697184-2909@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Beqalzi (Sonrotoclax): Phase 1/2 readout est. (NCT06697184)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1/2\, Mantle Cell Lymphoma.\nStud
 y: A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) Whe
 n Initiating Sonrotoclax in Participants Treated for Blood Cancers.\nEstim
 ated primary completion: 30 November 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06697184
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770698-2909@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Beqalzi (Sonrotoclax): Phase 1/2 readout est. (NCT07770698)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1/2\, Acute Myeloid Leukemia.\nSt
 udy: A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refra
 ctory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia\nEsti
 mated primary completion: 30 April 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07770698
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07277231-2909@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Beqalzi (Sonrotoclax): Phase 3 readout est. (NCT07277231)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 3\, Chronic Lymphocytic Leukemia.
 \nStudy: A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib 
 (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Prev
 iously Untreated Chronic Lymphocytic Leukemia\nEstimated primary completio
 n: February 2031. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/son
 rotoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07277231
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07554521-2010@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07554521)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemoth
 erapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroeso
 phageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial an
 d Ethnic Minority Patients in the United States\nEstimated primary complet
 ion: 31 December 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07554521
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06073821-2909@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20320229
DTEND;VALUE=DATE:20320301
SUMMARY:Beqalzi (Sonrotoclax): Phase 3 readout est. (NCT06073821)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 3\, Chronic Lymphocytic Leukemia.
 \nStudy: Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Com
 pared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymph
 ocytic Leukemia (CLL)\nEstimated primary completion: February 2032. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06073821
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
